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LEBER’S HEREDITARY OPTIC NEUROPATHY:
A CASE REPORT
Chi-Wu Chang, Chi-Huang Chang, and Mei-Lin Peng
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Leber’s hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease that primarily
affects the optic nerve, causing bilateral vision loss in juveniles and young adults. A 12-year-old boy had
complained of blurred vision in both eyes for more than 1 year. His best-corrected visual acuity was
0.08 in the right eye and 0.1 in the left. Ophthalmologic examination showed bilateral optic disc hyperemia
and margin blurring, peripapillary telangiectasis, and a relative afferent pupil defect in his right eye.
Fluorescein angiography showed no stain or leakage around the optic disc in the late phase. Visual field
analysis showed central scotoma in the left eye and a near-total defect in the right. Upon examination
of the patient’s mitochondrial DNA, a point mutation at nucleotide position 11778 was found, and the
diagnosis of LHON was confirmed. Coenzyme Q10 was used to treat the patient.
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Leber’s hereditary optic neuropathy (LHON) is a maternally
inherited mitochondrial disease that causes acute or
subacute bilateral vision loss in young adult males. The
point mutation at nucleotide position (np) 11778 of
mitochondrial DNA (mtDNA) was first identified by
Wallace et al in 1988 [1]. Several mtDNA mutations have
subsequently been identified. mtDNA mutations result in
deficiencies of energy generation within cells, especially in
tissues with high energy consumption, such as nerve fiber
cells. Clinically, the optic disc shows pseudoedema,
peripapillary telangiectasis, and central or cecocentral
scotoma. Fluorescein angiography typically shows no
fluorescein leakage or stain in the late phase. LHON is
easily mistaken for optic neuritis or compressive optic
neuropathy. Here, we present a case and describe the
clinical characteristics and current therapy for LHON.
CASE PRESENTATION
A 12-year-old boy had suffered from blurred vision of the
right eye for more than 1 year and visual acuity of the left eye
had begun to worsen 2 months previously. Despite proper
corrective lenses, his visual acuity became progressively more
blurred. The patient’s best-corrected visual acuity (BCVA)
was 0.08 in the right eye and 0.1 in the left. The ocular surface
and anterior segment, including the conjunctiva, cornea,
anterior chamber, iris, and lens, all appeared to be normal
under biomicroscopic examination. Intraocular pressure
was also within normal limits. However, a relative afferent
papillary defect was noted in his right eye, and bilateral
optic disc margin blurring with hyperemia and peripapillary
telangiectasis were found upon ophthalmoscopic exami-
nation (Figure 1). The patient’s medical records revealed no
congenital or systemic illness, no drug or substance abuse, and
no family history of poor vision. He had undergone bilateral
functional endoscopic sinus surgery (FESS) for chronic
paranasal sinusitis under general anesthesia 3 months before
he came to our department, and subjectively felt a worsening
of visual acuity after surgery.
Initially, intracranial lesions or inflammatory or
miscellaneous disorders of the optic nerve were suspected.
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Figure 1. Fundus photographs of the right (A) and left (B) eyes showing bilateral optic disc hyperemia and margin blurring, peripapillary
telangiectasis, and arteriole tortuosity.
 A B
Figure 2. Fluorescein angiography of the right (A) and left (B) eyes in the late stage showing no stain or leakage of fluorescein around the optic discs.
 A B
The patient consequently underwent laboratory
examination, visual field analysis, fluorescein angiography,
visual-evoked potential (VEP) examination, and magnetic
resonance imaging (MRI). Blood biochemistry, erythrocyte
sedimentation rate (ESR), and heavy metal screening were
all within normal limits. Imaging studies revealed no orbital
or intracranial lesions, and fluorescein angiography showed
no stain or leakage in the late phase (Figure 2), indicating
pseudoedema of the optic disc. Visual field examination
showed a near-total defect in the patient’s right eye and
central scotoma in the left (Figure 3). Both eyes showed
increased latency on VEP examination and color vision
abnormalities. Based on the clinical symptoms and signs,
LHON was suspected and mtDNA examination revealed a
point mutation at np 11778. As the patient is the only child
of the family and his mother had passed away years ago in
a traffic accident, it was difficult to trace the pedigree of the
mtDNA mutation. However, other family members of the
patient’s mother are under further investigation.
Six weeks later, the patient subjectively felt a deterio-
ration of vision in both eyes. Visual acuity was 0.03 in the
right eye and 0.08 in the left eye, and the visual field defect
in the left eye was enlarged. After coenzyme Q10 treatment,
visual acuity and visual field remained steady during the
follow-up period. Three months after the patient’s first
visit, his BCVA was 0.03 and 0.08 in the right and left eyes,
respectively, although he subjectively felt that his vision
had improved. Optic atrophy was noted in his right eye, but
peripapillary telangiectasis and disc margin blurring had
disappeared in both eyes.
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Figure 3. Humphrey visual fields of the right and left eyes showing near-total defect in the right eye and central scotoma in the left eye.
DISCUSSION
LHON, a maternally inherited mitochondrial disease, was
first identified by Wallace et al in 1988 [1], although it had
been described more than 100 years earlier (Von Grafe [2],
Leber [3]). In northeast England, the estimated prevalence
of LHON is 1 in 25,000 [4].
The first point mutation identified in mtDNA was a
single guanine to adenine transition mutation at np 11778.
Since then, several mutations in mtDNA have been
discovered [5]. However, only mutations at nps 11778,
3460, and 14484 have been proposed as primary mutations
[6], which alone can cause optic neuropathy. These three
primary mutations account for more than 95% of the LHON
pedigree in the study by Mackey et al [7]. In addition to
primary mutations, there are secondary mutations [5], which
together with primary mutations might play a role in
predisposing patients to optic neuropathy. Moreover, a
mixture of mutant and normal mtDNA molecules within a
cell gives rise to heteroplasmy, as first described by Lott et
al in 1990 [8]. Heteroplasmy results in differences between
individuals of the same family. That is, some will be
predisposed to vision loss and others will not. However, in
recent studies, no clear difference in disease severity was
found between heteroplasmic and homoplasmic patients
[9,10].
Among the primary mutations, the most prevalent, np
11778, accounts for 50% to 70% of all LHON patients [7,8,
11]. In Chinese patients, the ratio is much higher, with np
11778 mutations accounting for 92% of LHON patients, as
reported by Yen et al [12,13]. The np 3460 and np 14484
mutations have rarely been reported in Asian LHON
patients; the np 11778 mtDNA mutation in our case is
consistent with the findings of Yen et al.
The percentage of male predominance is about 71%
to 82% for np 11778. Most (70%) patients with np 11778
LHON will develop vision loss between 10 and 30 years
of age, and the average interval between the two eyes is
Leber’s hereditary optic neuropathy
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1.8 months [11,14]. Although X-linked factors have been
proposed to cause different rates of predominance between
male and female patients, no definite linkage has been
found [15].
Clinically, in the acute stage, LHON exhibits
peripapillary microangiopathy, optic disc pseudoedema,
no detectable staining or leakage around the optic disc
during fluorescein angiography, central or cecocentral visual
field defect, dyschromatopsia, and delayed response in
VEP. In the end stage, optic atrophy occurs.
Our case had several of the characteristics mentioned
above. However, many cases do not manifest all of these
typical features. Newman et al reported that only 58% of
patients show classic features of np 11778 LHON [14]. In
cases without microangiopathy, Hung et al suggested that
VEP is a good indicator for predicting onset of optic
neuropathy and vision loss [16].
The visual outcome of LHON has been investigated
in several studies [14,17–20]. For np 11778 mutations, as
in our patient, the final visual acuity in 98% of patients
is less than 20/200, and the average duration of progression
of vision loss in each eye was 3.7 months [14]. Prognosis
of LHON is dependent on the primary mtDNA mutation
[11,14]. It has been reported that the np 11778 mutation
is associated with poor visual outcome, whereas np
3460 and np 14484 mtDNA mutations are associated
with better visual prognosis [14,19,20]. Visual outcome is
best in patients with np 14484 mutations, with 71% of
all patients having a final visual acuity of at least 6/24.
However, Riordan-Eva et al found no difference in visual
prognosis between patients with np 11778 and np 3460 [11].
Visual outcome is independent of secondary mutation
[11,17,18]. This may be due to the interaction between
undiscovered genetic and environmental factors. It has
been proposed that environmental factors, including
exposure to certain substances, and tobacco and alcohol
consumption, may predispose LHON patients to vision
loss [21,22]. However, later studies have disputed these
opinions [23].
Although it has been reported that visual prognosis is
correlated with age at onset and that there is a favorable
visual outcome for childhood LHON [11,17,24], in our case
of early childhood onset, BCVA was 0.03 in the right eye
and 0.08 in the left eye.
There is no effective clinical treatment for LHON patients
to recover normal visual acuity. Many studies have tried to
increase mitochondrial energy production. However, their
effectiveness remains controversial. It has been reported
that idebenone treatment alone, or in combination with
vitamin B2 and vitamin C, shortens the period of visual
recovery. Unfortunately, there is no significant difference in
final visual acuity [25,26]. Huang et al reported significant
progress in BCVA within 4 months in a patient with
np 11778 mutation treated with coenzyme Q10 [27].
Currently, our patient is undergoing coenzyme Q10 therapy
(90 mg/d), but the actual clinical effect requires further
investigation. Regarding gene therapy, considerable
progress has been made in animal experiments and it might
be a possible solution to LHON. However, there are still
many difficulties to overcome before it can be applied in
clinical practice [28].
The case we present here had several typical symptoms
and signs to suggest LHON. However, in many other cases
in regular clinical practice, the diagnosis of LHON may not
be made due to the absence of a compatible family history
or typical clinical appearance. In addition, whether surgery
plays a role in predisposing a patient to the onset of LHON
is unknown. We strongly suggest that if young adult patients
have abnormal optic disc appearance or vessel changes
around the disc with unexplained vision loss, genetic
counseling should be seriously considered.
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